메뉴 건너뛰기




Volumn 3, Issue 3, 2002, Pages 289-309

Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CELECOXIB; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DICLOFENAC; E 3179; ESOMEPRAZOLE; ETORICOXIB; FLURBIPROFEN; LANSOPRAZOLE; LOSARTAN; LOSARTAN POTASSIUM; MULTIDRUG RESISTANCE PROTEIN; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; QUINIDINE; RABEPRAZOLE; RECOMBINANT ENZYME; ROFECOXIB; SULFAPHENAZOLE; SULFOTRANSFERASE; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

EID: 0035987212     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389200023337522     Document Type: Review
Times cited : (98)

References (221)
  • 51
    • 0009503852 scopus 로고    scopus 로고
    • Applications of heterologous expressed and purified human drug-metabolizing enzymes: An industrial perspective
    • edited by Woolf, T.F. Marcel Dekker, Inc
    • (1999) Handbook of Drug Metabolism , pp. 279-320
    • Rodrigues, A.D.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.